Unknown

Dataset Information

0

Aspartate aminotransferase to platelet ratio index as a prospective predictor of hepatocellular carcinoma risk in patients with chronic hepatitis B virus infection.


ABSTRACT: APRI (aspartate aminotransferase [AST] to platelet ratio index) is widely used to assess fibrosis and cirrhosis risk, especially in hepatitis C virus (HCV)-infected patients. Few studies have evaluated APRI and hepatitis B virus (HBV)-related hepatocellular carcinoma (HCC) risk. Prospective evidence is needed to assess whether APRI predicts HCC risk in HBV patients.In a prospectively enrolled clinical cohort of 855 HBV patients with a 1-year exclusion window (followed for >?1 year and did not develop HCC within 1 year), the predictive value of APRI in HCC risk was evaluated by Cox proportional hazards model using univariate and multivariate analyses and longitudinal analysis.Higher APRI prospectively conferred a significantly increased risk of HCC in univariate analysis (quartile analysis, P trend?=?2.9?×?10(-7) ). This effect remained highly significant after adjusting for common host characteristics but not cirrhosis (P trend?=?7.1?×?10(-5) ), and attenuated when cirrhosis is adjusted (P trend?=?0.021). The effect remained prominent when the analysis was restricted to patients with a more stringent 2-year exclusion window (P trend?=?0.008 in quartile analysis adjusting all characteristics including cirrhosis), indicating that the association was unlikely due to including undetected HCC patients in the cohort, thus minimizing the reverse-causation limitation in most retrospective studies. Longitudinal comparison demonstrated a persistently higher APRI value in HBV patients who developed HCC during follow-up than those remaining cancer free.APRI might be a marker of HCC risk in HBV patients in cirrhosis-dependent and -independent manners. Further studies are warranted to validate this finding and test its clinical applicability in HCC prevention.

SUBMITTER: Hann HW 

PROVIDER: S-EPMC4418451 | biostudies-literature | 2015 Jan

REPOSITORIES: biostudies-literature

altmetric image

Publications

Aspartate aminotransferase to platelet ratio index as a prospective predictor of hepatocellular carcinoma risk in patients with chronic hepatitis B virus infection.

Hann Hie-Won HW   Wan Shaogui S   Lai Yinzhi Y   Hann Richard S RS   Myers Ronald E RE   Patel Fenil F   Zhang Kejin K   Ye Zhong Z   Wang Chun C   Yang Hushan H  

Journal of gastroenterology and hepatology 20150101 1


<h4>Background and aim</h4>APRI (aspartate aminotransferase [AST] to platelet ratio index) is widely used to assess fibrosis and cirrhosis risk, especially in hepatitis C virus (HCV)-infected patients. Few studies have evaluated APRI and hepatitis B virus (HBV)-related hepatocellular carcinoma (HCC) risk. Prospective evidence is needed to assess whether APRI predicts HCC risk in HBV patients.<h4>Method</h4>In a prospectively enrolled clinical cohort of 855 HBV patients with a 1-year exclusion wi  ...[more]

Similar Datasets